© Copyright 2025 American Medical Association. All rights reserved.
Human leukocyte antigen (HLA) typing is a laboratory procedure that identifies specific antigens present on the surface of cells, particularly those involved in the immune response. This process focuses on the A, B, or C antigens, which are critical for determining tissue compatibility in various medical contexts. HLA typing is essential for identifying individuals who may be susceptible to certain diseases, as well as for assessing compatibility between potential stem cell, bone marrow, or solid organ transplant donors and recipients. Additionally, HLA typing plays a significant role in determining eligibility for specific vaccine or immunotherapy treatments. The antigens are categorized into Class I and Class II alleles, with current testing methods available for assessing susceptibility to diseases such as ankylosing spondylitis through HLA-B27 DNA typing. Other tests, including HLA-A, HLA-B, and HLA-C DNA typing, are utilized to evaluate the risk of autoimmune disorders and to ensure proper tissue matching for transplants. It is important to note that CPT® Code 86812 should be used when testing for a single antigen, while CPT® Code 86813 is designated for cases where multiple HLA antigens are analyzed.
© Copyright 2025 Coding Ahead. All rights reserved.
HLA typing is performed for several specific indications, including:
The procedure for HLA typing involves several key steps, which are detailed as follows:
After the HLA typing procedure, the patient may not require any specific post-procedure care, as the process is minimally invasive and typically does not result in significant side effects. However, it is important for healthcare providers to communicate the results of the HLA typing to the patient and discuss any implications for treatment or further testing. Patients may be advised to follow up with their healthcare provider to understand the significance of their HLA typing results, especially if they are being considered for transplant or specific therapies. Additionally, proper documentation of the results is essential for future medical decisions and potential donor-recipient matching.
Short Descr | HLA TYPING A B OR C | Medium Descr | HLA TYPING A/B/C MULTIPLE ANTIGENS | Long Descr | HLA typing; A, B, or C, multiple antigens | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 206 - Microscopic examination (bacterial smear, culture, toxicology) |
90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GZ | Item or service expected to be denied as not reasonable and necessary |
Date
|
Action
|
Notes
|
---|---|---|
2011-01-01 | Changed | Short description changed. |
Pre-1990 | Added | Code added. |